Patients’ characteristics.

<p>Ph+<b> = </b>Philadelphia chromosome positive.</p><p>PEM = pre existing mutations.</p

Sequences of ASO primers and corresponding annealing temperatures (bold nucleotides in the primers denote nucleotide changes corresponding to mutations).

*<p>Substitutions of amino acids; positions according to GenBank no. AAB60394for ABL type 1a.</p>**<p>Changes of nucleotide; positions according to GenBank no.M14752.</p>$<p>L (bp) = Primer length in base pairs.</p>#<p>A Tm =  Annealing temperature in degree Celsius.</p

Comparison of the frequencies of pre-existing BCR-ABL KD mutations and mutations detected after manifestation of imatinib resistance in CML patients.

<p>Comparison of the frequencies of pre-existing BCR-ABL KD mutations and mutations detected after manifestation of imatinib resistance in CML patients.</p

Clinical, cytogenetic, and molecular follow-up studies of CML patients with and without BCR-ABL PEMs who received imatinib treatment.

<p>N: number of patients, PEMs: pre-existing mutations; IM: imatinib; CHR: complete hematological response; PHR: partial hematological response; CCyR: complete cytogenetic response; MCyR: major cytogenetic response; minor CyR: minor cytogenetic response; MMR: major molecular response.</p